Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Greggi

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of Gynecologic Oncology|September 13, 2018
Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian studyStefano Uccella, Francesca Falcone, Stefano Greggi, et al.
Journal of the National Cancer Institute|April 21, 2005
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trialPierluigi Benedetti Panici, Angelo Maggioni, Neville Hacker, et al.
Gynecologic Oncology|December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trialGennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
Journal of the National Cancer Institute|November 27, 2008
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trialPierluigi Benedetti Panici, Stefano Basile, Francesco Maneschi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2021
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group studySabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, et al.
American Journal of Obstetrics and Gynecology|December 24, 2013
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinomaPierluigi Benedetti Panici, Stefano Basile, Maria Giovanna Salerno, et al.
The New England Journal of Medicine|February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian NeoplasmsPhilipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Gynecologic Oncology|September 13, 2018
Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian studyStefano Uccella, Francesca Falcone, Stefano Greggi, et al.
Journal of the National Cancer Institute|April 21, 2005
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trialPierluigi Benedetti Panici, Angelo Maggioni, Neville Hacker, et al.
Gynecologic Oncology|December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trialGennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
Journal of the National Cancer Institute|November 27, 2008
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trialPierluigi Benedetti Panici, Stefano Basile, Francesco Maneschi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2021
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group studySabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, et al.
American Journal of Obstetrics and Gynecology|December 24, 2013
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinomaPierluigi Benedetti Panici, Stefano Basile, Maria Giovanna Salerno, et al.
The New England Journal of Medicine|February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian NeoplasmsPhilipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
Pageof 9